Home » Stocks » CVM

Cel-Sci Corporation (CVM)

Stock Price: $18.00 USD -0.75 (-4.00%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
Market Cap 744.52M
Revenue (ttm) 543,473
Net Income (ttm) -32.94M
Shares Out 38.67M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $18.00
Previous Close $18.75
Change ($) -0.75
Change (%) -4.00%
Day's Open 19.03
Day's Range 18.02 - 19.50
Day's Volume 552,520
52-Week Range 8.10 - 40.91

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation reports first quarter fiscal 2021 financial results.

The Motley Fool - 1 month ago

Investors are betting that these three stocks could turn them into millionaires in incredibly short periods of time. Will they succeed?

Other stocks mentioned: AMC, BB
InvestorPlace - 1 month ago

CVM stock is on the move after Cel-Sci CEO Geert Kersten joined the battle against GME stock short-sellers. Here's what to know.

Business Wire - 1 month ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference

Business Wire - 1 month ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation issues letter to shareholders.

Business Wire - 2 months ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI reports fiscal 2020 financial results and clinical & corporate developments.

Seeking Alpha - 2 months ago

Data lock has been announced, and top line data is to be expected within a few weeks. Trial duration hints towards longer survival than Standard of Care.

Business Wire - 2 months ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference

Business Wire - 2 months ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces the closing of its $14.65 million bought deal.

Business Wire - 2 months ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Bought Deal Offering.

Seeking Alpha - 2 months ago

Data is Locked. NWBO's Data Lock announcement boosted their Market Cap to nearly $2B.

Business Wire - 2 months ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Update on Phase 3 Cancer Trial Results.

Business Wire - 3 months ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI's LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies.

Business Wire - 5 months ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation issues letter to shareholders.

Business Wire - 5 months ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at H.C.

Business Wire - 6 months ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation reports third quarter fiscal 2020 financial results.

Business Wire - 7 months ago

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment.

Seeking Alpha - 9 months ago

CEL-SCI: What's Next

Seeking Alpha - 9 months ago

Cel-Sci: A Zombie Biotech Company

Seeking Alpha - 9 months ago

CEL-SCI's Multikine: Can It Really Be This Good?

The Motley Fool - 10 months ago

Who has the upper ground in a war between investors and short-sellers about whether a biotech's clinical trial for treating head and neck cancer can succeed?

Seeking Alpha - 10 months ago

Cel-Sci: It's All Happening

Seeking Alpha - 11 months ago

CEL-SCI announced that it is developing an immunotherapy for COVID-19 based on its LEAPS peptide technology.

Seeking Alpha - 11 months ago

CEL-SCI: LEAPS & COVID-19

Seeking Alpha - 1 year ago

Cel-Sci: The Upside Is Still There

Seeking Alpha - 1 year ago

Cel-Sci: Little Known Drug Validates Multikine's Investigation Goals

Seeking Alpha - 1 year ago

CEL-SCI: Food For Thought Before The Big Day

Seeking Alpha - 1 year ago

CEL-SCI: The Homestretch

Seeking Alpha - 1 year ago

The mechanism of action for cytokines in helping the immune system respond to malignant growth in the head and neck has been well documented by medical research.

Seeking Alpha - 1 year ago

Multikine's Phase 3 trial accounts for the short half-lives of cytokines post administration, which may lead to significant improvements in its clinical profile compared to Phase 2.

Seeking Alpha - 1 year ago

The world's largest head and neck cancer study should have ended in late 2018 but patients appear to be living longer.

Seeking Alpha - 1 year ago

The world's largest head and neck cancer study should have ended in late 2018, but patients appear to be living longer.

Seeking Alpha - 1 year ago

Multikine is a cytokine-based immunotherapeutic compound intended to cure Head and Neck Squamous-Cell Carcinoma, which is currently being tested in a large Phase III trial.

The Motley Fool - 1 year ago

These stocks were huge winners last week. But can their momentum continue?

Other stocks mentioned: GTHX, PFE
Seeking Alpha - 1 year ago

May 8, 2019 Cel-Sci Corporation released a letter to investors indicating the Phase 3 Multikine trial had not yet reached its endpoint of 298 endpoints (deaths) in the two arms.

Seeking Alpha - 1 year ago

CEL-SCI's Multikine Phase III Trial in Squamous Cell Cancer of Head and Neck Continues as the End-Point Has Still Not Yet Been Reached.

About CVM

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and ... [Read more...]

Industry
Biotechnology
IPO Date
Jan 1, 1987
CEO
Geert Kersten
Country
United States
Stock Exchange
NYSEAMERICAN
Ticker Symbol
CVM
Full Company Profile

Financial Performance

In 2020, CVM's revenue was $597,427, an increase of 11.51% compared to the previous year's $535,776. Losses were -$30.28 million, 36.8% more than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for CVM is 19.00, which is an increase of 5.56% from the latest price.

Price Target
$19.00
(5.56% upside)